How Kaspi.kz’s Bigger Dividend With Flat Profits At Kaspi.kz (KSPI) Has Changed Its Investment Story

Kaspi.KZ

Kaspi.KZ

KSPI

0.00

  • Kaspi.kz has reported its second-quarter 2026 results, with revenue rising to KZT 1,112,152 million and net income holding roughly flat at KZT 258,889 million compared with a year earlier, alongside first-half revenue of KZT 2,192,782 million and net income of KZT 510,796 million.
  • At the same time, the company proposed lifting its quarterly dividend by 18% to KZT 1,000 per ADS, signalling that management is willing to return more cash to shareholders even as earnings remain broadly unchanged year on year.
  • Next, we’ll examine how Kaspi.kz’s higher proposed dividend, set against largely stable profits, reshapes its existing investment narrative and risk balance.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Kaspi.kz Investment Narrative Recap

To own Kaspi.kz, you need to believe its super app can keep deepening its role in payments, marketplace, and fintech, even as competition and regulation intensify. The latest results show strong revenue but flat earnings, and the proposed dividend hike does not materially change the near term story: the key catalyst remains execution on new verticals and international expansion, while the biggest immediate risk is that higher rates and regulatory shifts continue to weigh on margins.

Among recent developments, the proposed lift in the quarterly dividend to KZT 1,000 per ADS stands out against largely stable net income. That higher payout matters for the current narrative because Kaspi.kz is already offering a relatively high yield, and consensus expects only moderate earnings growth. If earnings do not keep pace, a richer dividend could tighten financial flexibility just as the company is investing in e-Grocery, Turkey, and other growth projects.

Yet beneath the higher dividend, there is a key risk investors should be aware of if profit growth stays muted while payout demands keep rising and...

Kaspi.kz's narrative projects KZT7025.9 billion in revenue and KZT1486.9 billion in earnings by 2029. This requires 17.8% yearly revenue growth and an earnings increase of roughly KZT416.4 billion from KZT1070.5 billion today.

Uncover how Kaspi.kz's forecasts yield a $96.96 fair value, a 3% upside to its current price.

Exploring Other Perspectives

KSPI 1-Year Stock Price Chart
KSPI 1-Year Stock Price Chart

Before this news, the most optimistic analysts were banking on Kaspi.kz lifting revenue to about KZT 7,672,400 million and earnings to roughly KZT 2,051,600 million by 2029, which is a far brighter scenario than the consensus view. Set against that, the risk that Kaspi.kz is still heavily tied to Kazakhstan’s economy shows how widely expectations can differ and why you may want to weigh several possible paths from here.

Explore 9 other fair value estimates on Kaspi.kz - why the stock might be worth as much as 93% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Kaspi.kz research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
  • Our free Kaspi.kz research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kaspi.kz's overall financial health at a glance.

No Opportunity In Kaspi.kz?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

  • The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
  • Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
  • AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.